Producers of Popular Antibacterial Soaps Must Prove Efficiency and Safety, Says FDA
The FDA is challenging the effectiveness of so-called “antibacterial” soaps, and has announced that it plans to give companies one year to prove that their products are both safe and more effective than the old stand-by, plain soap and water. Producers of the products in question will have to conduct clinical studies that indicate whether there are negative long term effects as a result of continued use. If the soaps prove to be unsafe the active ingredient will have to be removed from the soaps’ formula.
Antibacterial soap washes have been part of an ongoing debate in the U.S. for over 40 years now about whether antibacterial products, and the chemicals they contain, are over-used. There is also widespread concern that the extended use of the products help to increase the prevalence of super bugs and that some of the ingredients used in the washes, in particular triclosan, or triclocarban have been linked to both hormone imbalances and antibiotic resistance.
A senator from Massachusetts, Edward J. Markey, who pressed the FDA to subject the products to closer investigation, remarked in a statement that federal authorities have “acknowledged the potential for triclosan to interfere with the body’s thyroid hormone, which is important for brain development and function, particularly in children.”